[go: up one dir, main page]

SV2004001367A - Compuestos y procedimientos antitumorales ref.x-15365 - Google Patents

Compuestos y procedimientos antitumorales ref.x-15365

Info

Publication number
SV2004001367A
SV2004001367A SV2002001367A SV2002001367A SV2004001367A SV 2004001367 A SV2004001367 A SV 2004001367A SV 2002001367 A SV2002001367 A SV 2002001367A SV 2002001367 A SV2002001367 A SV 2002001367A SV 2004001367 A SV2004001367 A SV 2004001367A
Authority
SV
El Salvador
Prior art keywords
procedures
ref
antitumor compounds
compounds
antitumor
Prior art date
Application number
SV2002001367A
Other languages
English (en)
Inventor
Dios Alfonso De
Cora Sue Grossman
Philip Arthur Hipskind
Ho-Shen Lin
Karen Lynn Lobb
Deuralde Gamendia Beatriz Lopez
Jose Eduardo Lopez
Mary Margaret Mader
Michael Enrico Richett
Chuan Shih
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2004001367A publication Critical patent/SV2004001367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS ANTINEOPLASTICOS DE FORMULA; VER FORMULA, Y PROCEDIMIENTOS ANTINEOPLASTICOS
SV2002001367A 2001-10-25 2002-10-24 Compuestos y procedimientos antitumorales ref.x-15365 SV2004001367A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
SV2004001367A true SV2004001367A (es) 2004-02-24

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001367A SV2004001367A (es) 2001-10-25 2002-10-24 Compuestos y procedimientos antitumorales ref.x-15365

Country Status (33)

Country Link
US (2) US7084170B2 (es)
EP (1) EP1442030B1 (es)
JP (1) JP4464681B2 (es)
KR (1) KR100913471B1 (es)
CN (1) CN1298709C (es)
AR (1) AR037248A1 (es)
AT (1) ATE338033T1 (es)
AU (1) AU2002334817B2 (es)
BR (1) BR0212386A (es)
CA (1) CA2463300C (es)
CY (1) CY1106247T1 (es)
DE (1) DE60214413T2 (es)
DK (1) DK1442030T3 (es)
EA (1) EA006081B1 (es)
EC (1) ECSP045078A (es)
EG (1) EG26021A (es)
ES (1) ES2269816T3 (es)
HR (1) HRP20040371B1 (es)
HU (1) HUP0401638A3 (es)
IL (2) IL160851A0 (es)
MX (1) MXPA04003886A (es)
MY (1) MY130718A (es)
NO (1) NO20041316L (es)
NZ (1) NZ531136A (es)
PE (1) PE20030574A1 (es)
PL (1) PL208083B1 (es)
PT (1) PT1442030E (es)
SI (1) SI1442030T1 (es)
SV (1) SV2004001367A (es)
TW (1) TWI281916B (es)
UA (1) UA75716C2 (es)
WO (1) WO2003035629A1 (es)
ZA (1) ZA200403089B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007484B1 (ru) * 2001-06-11 2006-10-27 Вирокем Фарма Инк. Соединения и способы лечения или предупреждения инфекций flavivirus
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003104218A1 (en) * 2002-06-06 2003-12-18 Smithkline Beecham Corporation Nf-:b inhibitors
US7402608B2 (en) 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2006030947A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
CA2599301A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel use of sulfonamide compound in combination with angiogenesis inhibitor
DE602006021401D1 (de) 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
BRPI0610283A2 (pt) * 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
EP2015070A4 (en) 2006-04-20 2010-04-21 Eisai R&D Man Co Ltd Novel marker for sensitivity against sulfonamide compound
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101568538B (zh) 2006-11-15 2012-09-05 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
CN101675033A (zh) 2007-05-16 2010-03-17 霍夫曼-拉罗奇有限公司 芳基吡啶基磺酰胺衍生物，它们的制备和作为药剂的应用
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团（天津）股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法
WO2024251876A1 (en) * 2023-06-07 2024-12-12 KRæFTENS BEKæMPELSE PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS
WO2025031360A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
NZ238911A (en) * 1990-07-17 1993-10-26 Lilly Co Eli Furyl, pyrrolyl and thienyl sulphonyl urea derivatives, pharmaceutical compositions and intermediates therefor
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
ATE310738T1 (de) * 1996-07-05 2005-12-15 Us Gov Health & Human Serv Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
WO1998014440A1 (en) 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Also Published As

Publication number Publication date
MXPA04003886A (es) 2004-07-08
JP2005511547A (ja) 2005-04-28
CY1106247T1 (el) 2011-06-08
PL368234A1 (en) 2005-03-21
HRP20040371A2 (en) 2004-08-31
MY130718A (en) 2007-07-31
AR037248A1 (es) 2004-11-03
PL208083B1 (pl) 2011-03-31
SI1442030T1 (sl) 2006-12-31
US7250430B2 (en) 2007-07-31
HK1068337A1 (en) 2005-04-29
EP1442030A1 (en) 2004-08-04
PT1442030E (pt) 2006-12-29
US20060223871A1 (en) 2006-10-05
HRP20040371B1 (en) 2012-07-31
PE20030574A1 (es) 2003-07-03
IL160851A0 (en) 2004-08-31
CA2463300A1 (en) 2003-05-01
UA75716C2 (en) 2006-05-15
US20040198784A1 (en) 2004-10-07
NZ531136A (en) 2006-08-31
ATE338033T1 (de) 2006-09-15
EG26021A (en) 2012-12-10
DK1442030T3 (da) 2006-12-27
CN1298709C (zh) 2007-02-07
AU2002334817B2 (en) 2008-02-21
BR0212386A (pt) 2004-07-27
KR20040062583A (ko) 2004-07-07
IL160851A (en) 2009-11-18
HUP0401638A3 (en) 2012-09-28
KR100913471B1 (ko) 2009-08-25
JP4464681B2 (ja) 2010-05-19
DE60214413T2 (de) 2007-03-08
DE60214413D1 (de) 2006-10-12
CA2463300C (en) 2011-07-19
EP1442030B1 (en) 2006-08-30
EA006081B1 (ru) 2005-08-25
WO2003035629A1 (en) 2003-05-01
EA200400582A1 (ru) 2004-08-26
US7084170B2 (en) 2006-08-01
ECSP045078A (es) 2004-06-28
ES2269816T3 (es) 2007-04-01
ZA200403089B (en) 2005-04-22
CN1575286A (zh) 2005-02-02
HUP0401638A2 (hu) 2004-11-29
NO20041316L (no) 2004-03-30
TWI281916B (en) 2007-06-01

Similar Documents

Publication Publication Date Title
SV2004001367A (es) Compuestos y procedimientos antitumorales ref.x-15365
SV2003001076A (es) Compuestos y procedimientos antitumorales ref. x-14776
GB0124627D0 (en) Novel compounds
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
ECSP045082A (es) Formulación granular
ECSP034600A (es) Compuestos de lactama
NO20042279L (no) Kinazolinderivater som antitumormidler
NO20042288L (no) Kinazolinderivater som antitumormidler
MXPA03008968A (es) Fuente de iluminacion lineal.
MXPA03010007A (es) USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
CY1107759T1 (el) Λυοφιλισμενη συνταγοποιηση που περιλαμβανει ολανζαπινη
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
DE60215804D1 (de) 4-aminopyrimidine derivate
ITTO20020085U1 (it) Proiettore per veicoli.
NO20040515L (no) Luminescerende fosfor.
ITTO20020066V0 (it) Proiettore per veicoli.
HN2000000084A (es) Inhibidores de metaloproteasa.
DE60237360D1 (en) Glycopeptidantibiotika
ITTO20020067U1 (it) Proiettore per veicoli.
CY1115144T1 (el) Παραγωγα του uk-2a
HN2002000149A (es) Imidazotriazinas
ES1048305Y (es) Hebilla autoblocante.
GB0111551D0 (en) F.R.at source
HN2000000247A (es) Quimioterapia de combinacion
AU2002331425A1 (en) Suppressed drift interferometer